ALK and adenocarcinoma: Actionable alterations were commonly found in adenocarcinoma (EGFR activating mutation, ALK translocation and ROS1 translocation) and squamous cell carcinoma (FGFR1 amplification, PIK3CA amplification and SOX2 amplification), but were not detected in pulmonary LELC.